255 related articles for article (PubMed ID: 35757470)
21. LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β.
Zhao WJ; Zhu LL; Yang WQ; Xu SJ; Chen J; Ding XF; Liang Y; Chen G
Cancer Sci; 2021 Apr; 112(4):1624-1632. PubMed ID: 33540491
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological progression by directly targeting SOX11 and regulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways.
Wang Y; Liu BG; Zhou CX
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5863-5873. PubMed ID: 31298337
[TBL] [Abstract][Full Text] [Related]
23. CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway.
Gao LZ; Wang JQ; Chen JL; Zhang XL; Zhang MM; Wang SL; Zhao C
Appl Biochem Biotechnol; 2023 Nov; 195(11):6913-6926. PubMed ID: 36951936
[TBL] [Abstract][Full Text] [Related]
24. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma.
Gao H; Wang W; Li Q
Cancer Biol Ther; 2022 Dec; 23(1):369-377. PubMed ID: 35491899
[TBL] [Abstract][Full Text] [Related]
25. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.
Liu Y; Liu Q; Chen S; Liu Y; Huang Y; Chen P; Li X; Gao G; Xu K; Fan S; Zeng Z; Xiong W; Tan M; Li G; Zhang W
FASEB J; 2019 Nov; 33(11):11959-11972. PubMed ID: 31408612
[TBL] [Abstract][Full Text] [Related]
26. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].
Shang L; Jiang W; Zhang J; Wu W
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):665-672. PubMed ID: 35673909
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
Wu YC; Li SY; Jia YF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
[TBL] [Abstract][Full Text] [Related]
28. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
29. STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2.
Zhang D; Liu H; Wang W; Xu G; Yin C; Wang S
Cancer Biol Ther; 2022 Dec; 23(1):1-16. PubMed ID: 36316642
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
[TBL] [Abstract][Full Text] [Related]
31. Silencing of Long Non-coding RNA ENST00000606790.1 Inhibits the Malignant Behaviors of Papillary Thyroid Carcinoma through the PI3K/AKT Pathway.
Zuo Z; Liu L; Song B; Tan J; Ding D; Lu Y
Endocr Res; 2021 Feb; 46(1):1-9. PubMed ID: 32791924
[TBL] [Abstract][Full Text] [Related]
32. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of RET gene mediated EGFR signaling pathway on epithelial-mesenchymal transition, proliferation and apoptosis of papillary thyroid carcinoma cells.
Zhao YL; Yuan BQ; Shen GS
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8036-8047. PubMed ID: 32767330
[TBL] [Abstract][Full Text] [Related]
35. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways.
Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P
Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956
[TBL] [Abstract][Full Text] [Related]
36. M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway.
Lv J; Liu C; Chen FK; Feng ZP; Jia L; Liu PJ; Yang ZX; Hou F; Deng ZY
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34184083
[TBL] [Abstract][Full Text] [Related]
37. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.
Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
[TBL] [Abstract][Full Text] [Related]
38. Microrchidia family CW‑type zinc finger 2 promotes the proliferation, invasion, migration and epithelial‑mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N‑myc downstream regulated gene 1 promoter.
Zhang J; Yang Y; Dong Y; Liu C
Int J Mol Med; 2022 Feb; 49(2):. PubMed ID: 34913078
[TBL] [Abstract][Full Text] [Related]
39. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Li YJ; Wang Y; Wang YY
J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]